NEI
EPRX

Northwest & Ethical Investments’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Northwest & Ethical Investments’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41K Buy
+6,237
New +$43K ﹤0.01% 511

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Northwest & Ethical Investments's EPRX Position: Q2 2026 in Review

Northwest & Ethical Investments opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 6,237 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #511 among its holdings.

68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Northwest & Ethical Investments held 6,237 shares of Eupraxia Pharmaceuticals worth $41K as of Q2 2026.
  • Eupraxia Pharmaceuticals was a new Northwest & Ethical Investments position in Q2 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Northwest & Ethical Investments's portfolio in Q2 2026, its #511 holding.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.